Quick Answer
Neuphoria Therapeutics Inc. reported Total Revenue of $15.65 million for fiscal year 2025.
Neuphoria Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $15.65M | — | — | — | — | — |
| Revenue (ASC 606) | $15.65M | — | — | — | — | — |
| Net Income | -$369.6K +97.6% |
-$15.49M +27.5% |
-$21.38M | — | — | — |
| Diluted EPS | -$0.23 +98.8% |
-$18.62 -93000.0% |
-$0.02 | — | — | — |
| Total Assets | $28.59M +3.4% |
$27.65M -3.2% |
$28.56M -56.3% |
$65.31M +20.4% |
$54.26M | — |
| Cash and Equivalents | $14.21M +12.7% |
$12.61M +4.2% |
$12.10M | — | — | — |
| Stockholders Equity | $19.00M +8.6% |
$17.49M -20.5% |
$22.01M -43.9% |
$39.23M | — | — |
| R&D Expense | $9.01M -4.4% |
$9.42M -28.0% |
$13.07M -18.3% |
$16.00M +177.6% |
$5.76M -1.1% |
$5.83M |
| Operating Income | -$1.13M +93.7% |
-$17.89M +18.6% |
-$21.98M | — | — | — |
| Shares Outstanding | 1.98M +79.2% |
1.10M -99.9% |
1.47B | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $15.00M | — | +2163.4% |
| Revenue (ASC 606) | March 31, 2025 | $15.00M | — | +2163.4% |
| Net Income | December 31, 2025 | $1.86M | +195.9% | +118.8% |
| Diluted EPS | December 31, 2025 | -$0.77 | +57.0% | +82.5% |
| Total Assets | December 31, 2025 | $36.60M | +101.4% | +33.8% |
| Cash and Equivalents | December 31, 2025 | $22.17M | +410.3% | +62.4% |
| Stockholders Equity | December 31, 2025 | $29.70M | +116.0% | +137.4% |
| R&D Expense | December 31, 2025 | $697.7K | -59.8% | -81.6% |
| Operating Income | December 31, 2025 | -$4.06M | -9.6% | +28.2% |
| Shares Outstanding | December 31, 2025 | 5.38M | +230.2% | +128.1% |
- Neuphoria Therapeutics Inc. reported Total Revenue of $15.65 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. reported Revenue (ASC 606) of $15.65 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. reported Net Income of -$369.6 thousand for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +97.6% in Net Income compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Diluted EPS of $0.23 per share (loss) for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +98.8% in Diluted EPS compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Total Assets of $28.59 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +3.4% in Total Assets compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Cash and Equivalents of $14.21 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +12.7% in Cash and Equivalents compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Stockholders Equity of $19.00 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +8.6% in Stockholders Equity compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported R&D Expense of $9.01 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed a decrease of -4.4% in R&D Expense compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Operating Income of -$1.13 million for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +93.7% in Operating Income compared to the prior fiscal year.
- Neuphoria Therapeutics Inc. reported Shares Outstanding of 1.98 million shares for fiscal year 2025.
- Neuphoria Therapeutics Inc. showed an increase of +79.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: